Schizophrenia is a disabling chronic mental illness, consisting of the prodromal phase and 2 following psychotic onset, with the lifetime prevalence of 0.4% to 1.0% worldwide. 6, 7 The 3 majority of first-episode schizophrenia patients positively respond to antipsychotic treatment 4 with dopamine D2 receptor (DRD2) antagonists. 2 Increased dopamine synthesis was 5 observed in these responding patients, 3 suggesting the involvement of abnormal 6 dopaminergic signaling in the pathology of schizophrenia. Although epidemiologic studies 7 convincingly suggested the high genetic heritability of schizophrenia, 1 genome-wide 8 association studies (GWAS) have not succeeded in indicating the apparent association of 9 dopamine-related genes with schizophrenia. 8 In fact, those studies tended to obtain negative 1 0 results regarding the genetic associations with schizophrenia among the candidates proposed 1 1
by a variety of psycho-pharmacological hypotheses. 9 
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We recently demonstrated that analyses of the combinations of multiple functional 1 3 single nucleotide polymorphisms (SNPs) of the parent genes that are key factors in 1 4
dopaminergic signaling could be used to predict the risk of developing late-onset 1 5
treatment-resistant schizophrenia (L-TRS). 10 L-TRS may be due to antipsychotic-induced 1 6 dopamine supersensitivity; 11, 12 i.e., L-TRS may be caused by the compensatory up-regulation 1 7
of DRD2. [13] [14] [15] Because individuals with L-TRS may be correctly classified as having typical 1 8
dopamine-related schizophrenia, we evaluated the combination of dopamine-related 1 9
functional SNPs, i.e., rs10770141 of the tyrosine hydroxylase (TH) gene, rs4680 of the 2 0
catechol-O-methyltransferase (COMT) gene, and rs1800497, also called TaqIA, of the DRD2 2 1
gene (Table 1) . We identified two potent risk combinations for L-TRS; one is the double SNP reported that these individual SNPs may reflect the relatively higher TH gene expression 16 2 and COMT activity. 17 In addition, the individuals with A1(+) of rs1800497 could have lower 3 DRD2 gene expression. 18 Since these dopaminergic characteristics could be associated with 4 schizophrenia, we tested here whether these allelic combinations could pose a risk for the 5 development of the disease. 6
Our case-control study included 361 schizophrenic patients and 282 healthy controls 7 (Suppl. Table S1 ). None of the included SNPs showed an allelic or genotypic association with 8 schizophrenia (Suppl . Table S2 ). However, we found that the individuals with the triple 9
combination were significantly associated with schizophrenia (odds ratio [OR] 5.56, 95% Although we observed that none of the single SNPs was associated with schizophrenia, 1 5
a finding that is consistent with most of the literature, the significant association of the unique 1 6
triple combination might indicate that individuals with schizophrenia have some inborn 1 7
dopaminergic properties. Individuals with T(+) and Met(−) might be expected to show 1 8
relatively higher dopamine synthesis and more rapid dopamine degradation, which also 1 9
suggests that there are more dynamic alterations in dopamine concentrations at the synaptic 2 0
cleft. In addition, carrying A1(+) might be associated with a lower presynaptic DRD2 density 2 1
and consequently an enhanced dopamine release due to the attenuated negative feedback 2 2
loops. 19 Thus, these individuals might exhibit relatively more pulsatile dopamine signaling. It is known that repeated exposure to dopamine agonists (such as psychostimulants 20 ) 1 and/or stressors 21 causes sensitization. The term 'sensitization' means a progressive and 2 long-lasting amplification of the behavioral and neurochemical response 22 and has been 3 argued to play a pathogenic role in causing not only psychosis but also schizophrenia. [23] [24] [25] In 4 fact, it is clinically suggested that frequent exposure to stress poses a risk for prodromal 5 symptoms and schizophrenia. 26, 27 Individuals with schizophrenia were reported to release 6 greater amounts of dopamine in response to stress. 6 Individuals who carry the risk genetic 7 combination might demonstrate similar dopaminergic pathogenesis, since relatively rapid 8 pulsatile signaling could be caused repeatedly in response to daily stressors. This similarity in 9 dopaminergic pathogenesis could contribute to sensitization and be a reason for the increased 1 0 likelihood of schizophrenia onset. It may also be well consistent with the observations that 1 1
both genetic and environment factors seem to present risks for schizophrenia. 28,29 1 2
Our pathological hypothesis of schizophrenia demonstrated in this report accurately 1 3
accounts for the recently proposed clinical picture of schizophrenia. 6, 25 Assuming that the 1 4
sensitization to internal dopamine is somehow involved in the pathogenic mechanism of 1 5
schizophrenia, the identification of the at-risk individuals at a preclinical stage might provide 1 6
psychiatrists a pivotal chance to prevent the onset by managing the individual's pulsatile 1 7
dopamine activities. The risk genotypic combinations discovered in the present study were 1 8 detected in only 4.0% of the schizophrenic patients. However, we speculate that the inclusion 1 9
rate could be improved by evaluating better combinations of other functional SNPs related to 2 0 the dopamine pathway.
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In addition, although the lowest MAF (5.7%, of rs10770141) was the apparently 2 2
narrowing polymorphism in our study population, the Trans-Omics for Precision Medicine 2 3 7 project recently reported to the U.S. National Center for Biotechnology Information that the 1 MAF was estimated to be as large as 42.9% in the global population, suggesting its 2 applicability. 30 In the present study, we focused on the genetic variants related to the 3 dopaminergic system, but our approach will be appropriate to assess other candidates related 4
to different neurotransmissions including gamma-aminobutyric acid (GABA) and 5 glutamatergic signaling. 6
There are some issues to be considered as study limitations. First, the mean age of our 7 healthy control subjects was significantly lower than that of the patients. Although 8 schizophrenia generally emerges during adolescence, our controls could still include potent 9 false negatives. However, the impact may be limited because (1) the mean age of disease 1 0
onset was significantly younger than the mean age of the controls, and (2) the lifetime 1 1
prevalence of schizophrenia was estimated to be as small as 0.4%-1.0%. In addition, our 1 2
sample size was large enough to allow us to evaluate our results, but further validations are 1 3
clearly expected -including those obtained for large and multi-ethnic populations. 1 4
In conclusion, we conducted a case-control study to investigate the association of 1 5
functional SNPs related to dopamine transmission with schizophrenia. Our analyses revealed 1 6
that the combination of the SNPs related to TH, COMT and DRD2 genes was significantly 1 7
associated with the onset of schizophrenia. We hypothesize that the present genetic 1 8
combination characterizes dopamine transmission. The findings are important because of 1 9
their potential to bring new insights to risk prediction and the development of new treatment 2 0 methods for schizophrenia. However, future studies are necessary to test our findings. . Table S1 ). 
